Abstract
Background: The relationship between the use of non-vitamin K antagonist oral anticoagulants (NOACs) and the impairment of cognition in atrial fibrillation (AF) remains unknown.Methods: A comprehensive database search of Medline, Embase, Cochrane Library databases, and ClinicalTrials.gov Website was performed for randomized controlled trials (RCTs) reporting cognitive impairment events and observational nationwide database studies reporting adjusted hazard ratio (HR) in AF patients with NOACs. The primacy outcome was a composite of any cognitive impairment. Summary of HRs and 95% confidence intervals (95%CI) were calculated using the fixed- and random-effects models. Subgroup analyses were undertaken according to the individual NOACs, study types, and duration of follow-up.Results: Finally, eight studies including 97,595 patients (77,643 patients in 6 RCTs and 19,952 patients in 2 observational database studies) met the inclusion criteria, among which 55,337 (56.7%) patients were receiving NOACs and 42,258 (43.3%) patients were receiving vitamin K Antagonists (VKAs) or acetylsalicylic acid. The results showed a borderline significant association between the use of NOACs and the lower risk of cognitive impairment when compared with VKAs/ acetylsalicylic acid (HR: 0.80, 95%CI: 0.63–0.98 for fixed-effects model; HR: 0.77; 95%CI: 0.53–1.01 for random-effects model), with no significant heterogeneity between the studies (I2 = 39.4%, P = 0.12). The results were consistent across the key subgroups (Pinteraction > 0.05 for each).Conclusions: The results indicated that the use of NOACs might lower the tendency on the risk of cognitive impairment in comparison to VKAs/acetylsalicylic acid, and further RCTs and real-world studies are required on an urgent basis to obtain a robust result.
Highlights
Atrial fibrillation (AF) and cognitive impairment, which predominantly affect the elderly, are expected to be among the most prominent global epidemiological trends in the twentyfirst century, bringing an overwhelming burden to the health care system worldwide (Dietzel et al, 2018)
Databases of Medline, Embase, and Cochrane Library were searched to identify all the potentially eligible studies from inception to April 23rd, 2018 with the following searching strategy: “dabigatran” or “Pradaxa” or “rivaroxaban” or “Xarelto” or “apixaban” or “Eliquis” or “edoxaban” or “Savaysa” or “betrixaban” or “Bevyxxa” or “Non-vitamin K antagonist oral anticoagulants” or “non-vitamin K antagonist oral anticoagulants (NOACs)” or “direct oral anticoagulants” or “DOACs” or “novel oral anticoagulants” or “new oral anticoagulants” or “factor Xa inhibitors” or “factor II a inhibitors” in combination with “atrial fibrillation” or “AF.” In addition, unpublished trials were identified from the website, ClinicalTrials.gov
The characteristics of the 2 database studies are outlined in Table 2, consisting of 9,976 patients with dabigatran treatment and 9,976 patients with warfarin treatment
Summary
Atrial fibrillation (AF) and cognitive impairment, which predominantly affect the elderly, are expected to be among the most prominent global epidemiological trends in the twentyfirst century, bringing an overwhelming burden to the health care system worldwide (Dietzel et al, 2018). These two diseases share many common risk factors (hypertension, diabetes mellitus, vascular disease, and heart failure), and growing evidences suggest that AF is strongly associated with the increased risk of cognitive dysfunction and dementia (Jacobs et al, 2017; Dagres et al, 2018; Pastori et al, 2018). The relationship between the use of non-vitamin K antagonist oral anticoagulants (NOACs) and the impairment of cognition in atrial fibrillation (AF) remains unknown
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
